Effect of Anti-Programmed Cell Death Protein-1 Antibody Combined with Paclitaxel on Cervical Cancer via Phosphoinositolide 3-Kinase/Protein Kinase B Pathway in Rats

CHONG SHI*, G. ZHANG†, LIYAN PENG‡ AND K. ZHANG§

Department of Prenatal Diagnosis and Genetic Diagnosis Center, Tangshan Maternal and Child Health Care Hospital, †Department of Graduate, North China University of Science and Technology, ‡Department of Pharmacy Tangshan Maternal and Child Health Care Hospital, Tangshan, Hebei 063000, §Ren Sheng Zhong Chuang Marketing Consultant (Shanghai) Co., Ltd., Shanghai 200435, P. R. China

Shi et al.: Anti-Programmed Cell Death Protein 1 Antibody and Paclitaxel in Cervical Cancer

The therapeutic effect of combined drugs on cervical cancer has been confirmed. Whether anti-programmed cell death protein 1 antibody combined with paclitaxel mediates the phosphoinositolide 3-kinase-protein kinase B pathway to regulate cervical cancer still needs further research. 20 nude mice received subcutaneous administration of Henrietta Lacks cells to establish cervical cancer model. Which was then assigned to blank control group, control group A (programmed cell death protein 1 antibody (5 mg/kg) administration), control group B (paclitaxel) and observation group (programmed cell death protein 1 antibody combined with paclitaxel) followed by analysis of cell proliferation, apoptosis, expression of phosphoinositolide 3-kinase-protein kinase B signaling related proteins and messenger ribonucleic acids. Observation group had lowest tumor size, highest cell proliferation inhibition rate and cell apoptosis, which were all reversed in blank group with largest tumor size, lowest cell proliferation inhibition rate and cell apoptosis. There was no difference between control group A and control group B (p>0.05). The expressions of phosphoinositolide 3-kinase, protein kinase B, tumor protein p53 and tumor protein p21 were lowest in observation group and highest in blank group. In addition, control group had no significant difference with control group B (p>0.05). Anti-programmed cell death protein 1 antibody combined with paclitaxel may inhibit the activity of phosphoinositolide 3-kinase-protein kinase B signaling, thereby downregulating phosphoinositolide 3-kinase, protein kinase B, tumor protein p53 and tumor protein p21, controlling cervical cancer cell division, promoting cell apoptosis and finally exerting anti-tumor effects.

Key words: Cervical cancer, paclitaxel, programmed death protein-1, phosphoinositolide 3-kinase-protein kinase B pathway

Cervical cancer is one of the common tumor diseases, with high mortality and incidence[1]. At present, comprehensive treatment methods are mainly used clinically, combining surgery with chemotherapy, etc., to a certain extent, can effectively prolong the survival time of patients[2]. Programmed death protein-1 (PD-1) receptors mainly work in conjunction with their programmed death-ligand 1 (PD-L1) to regulate the proliferation activity of T cells and the secretion of related cytokines, thereby controlling the body’s immune response. For tumor patients, the expression of PD-L1 increases, which promotes the apoptosis of T cells expressing PD-L1 molecules and finally causes the escape phenomenon of related tumor cells to play a regulatory role in the disease[3]. For the occurrence and development of cervical cancer, PD-1 antibody and PD-L1 ligand can participate in the immune response of cervical cancer and it is related to the prognosis of cervical cancer patients. PD-1 antibody is used as a target and can play an anti-tumor effect and at the same time, it can also regulate the immunotoxicity in the body, but whether it can be used as a target

*Address for correspondence
E-mail: 18631530300@163.com

Accepted 18 August 2021
Revised 13 February 2021
Received 27 January 2020
Indian J Pharm Sci 2021;83(4):823-829
for the treatment of cervical cancer requires further research\(^\text{[4]}\). Paclitaxel has anti-tumor effects, mainly because paclitaxel can affect the balance of tubulin and dimers, thereby promoting the polymerization of tubulin, avoiding tubulin depolymerization and further promoting cell apoptosis. It is also used in breast cancer. In patients with cervical cancer, the mechanism of treatment for patients with cervical cancer is still unclear to be studied\(^\text{[5]}\). In the study of Che et al.\(^\text{[6]}\), they stated that cervical cancer cells are mainly derived from cervical epithelial cells and that cervical cancer has a certain relationship with the phosphoinositide 3-kinase-protein kinase B (PI3K-Akt) pathway, which is generally manifested as the inhibition of cell apoptosis. Regarding the apoptosis process of cervical cancer cells, mediation and intervention are currently effective ways to control cervical cancer. However, whether anti-PD-1 antibody combined with paclitaxel has a therapeutic effect on cervical cancer through mediating the PI3K-Akt pathway, needs to be further explored.

### MATERIALS AND METHODS

#### Materials and instruments:

Henrietta Lacks (Hela) cell (Tongpai (Shanghai) Biotechnology), PD-1 antibody (Shanghai Saimai Biotechnology), paclitaxel (Shandong Lukangchenxin), hematoxylin reagent, eosin stain (Nanjing Dosif), terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) reagent (Xiamen) Xinchuang), cell lysate (Shanghai Liji), phosphate buffered saline (PBS) (Zhejiang Xinfu Pharmaceutical).

Inverted microscope (Bio-IEK), glutamine, dual luciferase kit, penicillin (Ribo biological company); transwell kit (Best Bio); Lipofectamine\(^\text{TM}\) 2000 (Sigma); 0.25 \% trypsin, micro RNA (miRNA) 64 inhibitor, miRNA-64 mimics (Sigma); quantitative polymerase chain reaction (PCR) reagents (Sigma); fetal bovine serum, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Gibco); X-box binding protein 1 (XBP1), protein extraction kit (Bio-TEK Instruments).

#### Establishment of cervical cancer transplantation tumor model:

20 nude mice were selected and an appropriate amount of Hela cells were subcutaneously injected into the back of the rat to detect the size of the rat tumor tissue. The volume of tumor tissue=0.52×a×b\(^2\), where a represents the long diameter and b represents the short diameter\(^\text{[7]}\).

#### Grouping and dosing schedule:

20 rats were randomly selected and divided into blank group, control group A, group B and observation group. Among them, the blank group was given only an appropriate amount of physiological saline solution, the control group A was given PD-1 antibody (53 mg/kg) via intraperitoneal injection and the control group B was also given the same dose by intraperitoneal injection of paclitaxel. The observation group was given the same dose of PD-1 antibody combined with paclitaxel.

#### Detection of tumor volume:

After 5 d, the size of tumor tissue was measured every 3 d and after 15 d, tumor tissue was taken for subsequent experiments.

#### HE staining tumor tissue:

Take the above-mentioned tumor tissue, fix, PBS, hematoxylin dip, microscope observation, eosin staining and mount. Take the above mentioned transplanted tumor tissue, give it an appropriate amount of formaldehyde solution for fixation and then place it in a liquid nitrogen tank for standby, take the nude mouse heart, lung, liver, spleen, kidney and other tissues and then apply an appropriate amount of formaldehyde solution for the fixation operation. Use tap water for cleaning and apply appropriate amount of alcohol solution for dehydration, namely 70 \%, 80 \%, 90 \% and 100 \%, xylene and appropriate amount of paraffin for embedding. HE staining: Put the above-mentioned tissues in the oven, after 90 min, apply appropriate amount of xylene I and II for dewaxing and then add alcohol I and II, wash with double distilled water, stain with hematoxylin, wash with tap water and eosin dyeing, washing with tap water, adding 70 \%, 80 \%, 95 \% alcohol in the order, respectively, for 5 min, then respectively giving 95 \% alcohol II, 100 \% alcohol I and 100 \% alcohol II for 10 min and then giving appropriate amounts of xylene I, II, 10 min in all, again using gum for mounting operation, using an optical microscope to observe the morphology of each tissue.

#### Cell counting kit-8 (CCK-8) assay:

Under normal environment, cervical cancer cells were cultured and after 72 h, 100 µl 10 \% CCK-8 was added for 2 h followed by measuring the absorption value. Growth inhibition rate (%)=(Optical density (OD) control group−OD experimental group)/OD control group×100 \%.
TUNEL staining:
Take the cells, PBS, 3 times, 5 min/time, add Triton X-100, 3 min, PBS, 3 times, 5 min/time, culture in a dark environment and then wash with an appropriate amount of PBS solution, 3 times, 5 min/time, give proper amount of glycerin for sealing operation.

Western blot:
Cells were inoculated. After inoculation, cells were collected when reaching a confluence of 90% and lysed to extract cell protein which was then quantified and separated on sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) for western blot analysis using primary antibodies (PI3K, Akt, tumor protein p53 (p53) and tumor protein p21 (p21), dilution ratios are all 1:500).

Reverse transcription polymerase chain reaction (RT-PCR):
RNA was extracted followed by reverse transcription and PCR amplification with conditions: 95° 10 min, 1 cycles; 95° 15 s, 60° 60 s, 40 cycles. Gene was analyzed using 2^\(-\Delta\Delta Ct\) method and β-actin was the reference. The primer sequences were shown in Table 1.

Observation indicators:
Observe the cell proliferation activity, number and apoptosis number of each group, observe the expression of PI3K-Akt pathway related proteins and mRNA in each group.

Statistical methods:
Statistical package for the social sciences (SPSS) 26.0 software analyzed the data which were described as mean±standard deviation and assessed by F test, p<0.05 indicates a significance.

RESULTS AND DISCUSSION
Anti-PD-1 antibody combined with paclitaxel drugs decrease tumor tissue size. The tumor volume test results showed that after administration, tumor tissue size from the 1st to the 15th d of each group was compared and there were significant differences. Among them, observation group had smallest tumor tissue size, the blank group had the largest size without difference between control group A and control group B (p>0.05) (Table 2 and fig. 1).

Anti-PD-1 antibody combined with paclitaxel drugs inhibit the proliferation of cervical cancer cells and promote apoptosis. The CCK-8 test results showed that the cell inhibition rate of observation group was highest at different time points. In addition, comparison between the control group A and the control group B showed no difference (p>0.05) (Table 3 and fig. 2).

The TUNEL test results showed that observation group had highest number of apoptosis, blank group had lowest number without difference between control group A and control group B (p>0.05) (Table 4).

Anti-PD-1 antibody combined with paclitaxel regulate PI3K-Akt signaling pathway, thereby exerting a therapeutic effect on cervical cancer cells. Western blot and RT-PCR results showed that the expression of PI3K-Akt signaling pathway related proteins was lowest in observation group and highest in blank group. In addition, compared with control group B, control group A had no significant difference (p>0.05) (Table 5 and fig. 3).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin</td>
<td>5’-ctgattccgtctccttggttc-3’</td>
<td>5’-ctgattccgtctccttggttc-3’</td>
</tr>
<tr>
<td>PI3K</td>
<td>Forward</td>
<td>5’-ctgattccgtctccttggttc-3’</td>
</tr>
<tr>
<td>Akt</td>
<td>Reverse</td>
<td>5’-ctgattccgtctccttggttc-3’</td>
</tr>
<tr>
<td>p-Akt</td>
<td>Forward</td>
<td>5’-ctgattccgtctccttggttc-3’</td>
</tr>
<tr>
<td>p53</td>
<td>Reverse</td>
<td>5’-ctgattccgtctccttggttc-3’</td>
</tr>
<tr>
<td>p21</td>
<td>Forward</td>
<td>5’-ctgattccgtctccttggttc-3’</td>
</tr>
<tr>
<td>p-PI3K</td>
<td>Reverse</td>
<td>5’-ctgattccgtctccttggttc-3’</td>
</tr>
</tbody>
</table>

TABLE 1: PRIMER SEQUENCE

<table>
<thead>
<tr>
<th>Gene</th>
<th>Length (base pair (bp))</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin</td>
<td>105</td>
</tr>
<tr>
<td>PI3K</td>
<td>126</td>
</tr>
<tr>
<td>Akt</td>
<td>78</td>
</tr>
<tr>
<td>p-Akt</td>
<td>133</td>
</tr>
<tr>
<td>p53</td>
<td>111</td>
</tr>
<tr>
<td>p21</td>
<td>103</td>
</tr>
<tr>
<td>p-PI3K</td>
<td>121</td>
</tr>
</tbody>
</table>
### TABLE 2: CHANGES IN TUMOR TISSUE SIZE OF RATS IN EACH GROUP (cm³)

<table>
<thead>
<tr>
<th>Group</th>
<th>Sample size</th>
<th>1 d</th>
<th>3 d</th>
<th>6 d</th>
<th>9 d</th>
<th>12 d</th>
<th>15 d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank</td>
<td>5</td>
<td>1.15±0.07</td>
<td>1.27±0.06</td>
<td>1.38±0.16</td>
<td>1.57±0.14</td>
<td>1.65±0.13</td>
<td>1.86±0.16</td>
</tr>
<tr>
<td>Control A</td>
<td>5</td>
<td>1.18±0.05</td>
<td>1.17±0.05</td>
<td>0.97±0.08</td>
<td>0.86±0.05</td>
<td>0.76±0.12</td>
<td>0.47±0.07</td>
</tr>
<tr>
<td>Control B</td>
<td>5</td>
<td>1.26±0.07</td>
<td>1.17±0.06</td>
<td>1.08±0.08</td>
<td>0.89±0.07</td>
<td>0.78±0.05</td>
<td>0.54±0.08</td>
</tr>
<tr>
<td>Observation</td>
<td>5</td>
<td>1.16±0.13</td>
<td>1.07±0.08</td>
<td>0.98±0.06</td>
<td>0.76±0.11</td>
<td>0.48±0.12</td>
<td>0.22±0.07</td>
</tr>
</tbody>
</table>

F: 3.793 12.342 19.307 43.380 139.000 186.013
p: <0.001 <0.001 <0.001 <0.001 <0.001 <0.001

Blank vs. control A: 0.031 0.002 0.029 0.000 0.000 0.000
Blank vs. control B: 0.005 0.002 0.057 0.000 0.000 0.001
Blank vs. observation: 0.453 0.000 0.024 0.000 0.000 0.000
Control A vs. control B: 0.078 0.840 0.451 0.564 0.782 0.067
Control A vs. observation: 0.572 0.028 0.270 0.894 0.000 0.004
Control B vs. observation: 0.026 0.042 0.270 0.111 0.000 0.000

### TABLE 3: COMPARISON OF CERVICAL CANCER CELL PROLIFERATION INHIBITION RATE (%)

<table>
<thead>
<tr>
<th>Group</th>
<th>Sample size</th>
<th>24 h</th>
<th>48 h</th>
<th>72 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Control A</td>
<td>5</td>
<td>10.84±1.26</td>
<td>20.43±3.26</td>
<td>36.19±3.44</td>
</tr>
<tr>
<td>Control B</td>
<td>5</td>
<td>11.42±1.19</td>
<td>22.43±3.19</td>
<td>35.21±3.37</td>
</tr>
<tr>
<td>Observation</td>
<td>5</td>
<td>34.28±3.78</td>
<td>48.28±6.29</td>
<td>50.91±5.87</td>
</tr>
</tbody>
</table>

F: 138.101 116.478 223.850
p: <0.001 <0.001 <0.001

Blank vs. control A: 0.000 0.000 0.000
Blank vs. control B: 0.000 0.001 0.000
Blank vs. observation: 0.001 0.001 0.000
Control A vs. control B: 0.943 0.998 0.237
Control A vs. observation: 0.003 0.006 0.000
Control B vs. observation: 0.003 0.003 0.000

---

Fig. 1: Hematoxylin-eosin (HE) staining rat tumor tissue (×100), (A) Blank group; (B) Control group A; (C) Control group B; (D) Observation group; (E) Rats before administration
In this study, in order to explore the effect of anti-PD-1 antibody combined with paclitaxel on cervical cancer rats by regulating the PI3K-Akt pathway, the rats were first induced to cervical cancer using Hela cells. After drugs were given, the rats were further tested. Tumor tissue size, the results showed that after administration, the tumor tissue size of each group was compared from the 1st to the 15th d and there were significant differences. Among them, the observation group had the smallest tumor tissue size, the blank group was the largest and the control group A and the control group B, showed no difference, indicating that anti-PD-1 antibody combined with paclitaxel can significantly inhibit the growth of tumor tissue and the combined effect is significantly

**TABLE 4: COMPARISON OF THE NUMBER OF APOPTOSIS IN EACH GROUP (%)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Sample size</th>
<th>24 h</th>
<th>48 h</th>
<th>72 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank</td>
<td>5</td>
<td>1.08±0.02</td>
<td>1.04±0.01</td>
<td>1.07±0.03</td>
</tr>
<tr>
<td>Control A</td>
<td>5</td>
<td>10.43±1.14</td>
<td>20.23±3.34</td>
<td>36.25±3.23</td>
</tr>
<tr>
<td>Control B</td>
<td>5</td>
<td>11.24±1.23</td>
<td>22.51±3.27</td>
<td>35.32±3.43</td>
</tr>
<tr>
<td>Observation</td>
<td>5</td>
<td>33.45±2.36</td>
<td>48.37±6.32</td>
<td>50.62±5.63</td>
</tr>
</tbody>
</table>

F       511.797 356.504 518.522
p       0.000 0.000 0.000
Blank vs. control A p 0.002 0.002 0.000
Blank vs. control B p 0.000 0.000 0.000
Blank vs. observation p 0.000 0.000 0.000
Control A vs. control B p 0.978 0.710 1.000
Control A vs. observation p 0.000 0.000 0.000
Control B vs. observation p 0.000 0.000 0.000

**TABLE 5: CHANGES IN THE EXPRESSION OF PI3K-AKT SIGNALING PATHWAY RELATED PROTEINS (%)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Sample size</th>
<th>PI3K</th>
<th>AKT</th>
<th>p-Akt</th>
<th>p-PI3K</th>
<th>p53</th>
<th>p21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank</td>
<td>5</td>
<td>1.58±0.12</td>
<td>1.54±0.11</td>
<td>1.37±0.13</td>
<td>1.64±0.04</td>
<td>1.75±0.05</td>
<td>1.67±0.06</td>
</tr>
<tr>
<td>Control A</td>
<td>5</td>
<td>1.03±0.04</td>
<td>1.23±0.04</td>
<td>1.25±0.03</td>
<td>1.06±0.03</td>
<td>1.05±0.04</td>
<td>1.08±0.02</td>
</tr>
<tr>
<td>Control B</td>
<td>5</td>
<td>1.04±0.03</td>
<td>1.01±0.07</td>
<td>1.02±0.03</td>
<td>1.04±0.04</td>
<td>1.06±0.01</td>
<td>1.04±0.08</td>
</tr>
<tr>
<td>Observation</td>
<td>5</td>
<td>0.45±0.06</td>
<td>0.37±0.02</td>
<td>0.62±0.03</td>
<td>0.38±0.04</td>
<td>0.41±0.06</td>
<td>0.42±0.05</td>
</tr>
</tbody>
</table>

F       492.526 555629.170 128.444 2.308 517556.105 506.379
p       0.000 0.000 0.000 0.115 0.000 0.000
Blank vs. control A p 0.000 0.000 0.720 0.104 0.000 0.000
Blank vs. control B p 0.000 0.000 0.000 0.551 0.000 0.000
Blank vs. observation p 0.000 0.000 0.000 0.241 0.000 0.000
Control A vs. control B p 0.000 0.000 0.000 0.033 0.634 0.368
Control A vs. observation p 0.000 0.000 0.000 0.619 0.000 0.000
Control B vs. observation p 0.000 0.000 0.000 0.087 0.000 0.000

**Fig. 2:** Cell proliferation inhibition rate at different time points in each group.

In this study, in order to explore the effect of anti-PD-1 antibody combined with paclitaxel on cervical cancer rats by regulating the PI3K-Akt pathway, the rats were first induced to cervical cancer using Hela cells. After drugs were given, the rats were further tested. Tumor tissue size, the results showed that after administration, the tumor tissue size of each group was compared from the 1st to the 15th d and there were significant differences. Among them, the observation group had the smallest tumor tissue size, the blank group was the largest and the control group A and the control group B, showed no difference, indicating that anti-PD-1 antibody combined with paclitaxel can significantly inhibit the growth of tumor tissue and the combined effect is significantly
better than the treatment effect of single drug and it also indicates that the cervical cancer model is successfully made and can be used for follow-up experiments.

This study further explored the effect of anti-PD-1 antibody combined with paclitaxel on cervical cancer cells. The results showed that the inhibition rate of cell proliferation and cell apoptosis was the highest in observation group at different time points and lowest in blank group. The results of this study further indicate that the anti-PD-1 antibody combined with paclitaxel can significantly inhibit the proliferation of cervical cancer cells, while effectively promoting apoptosis of cervical cancer cells and has an effect on the proliferation of cervical cancer cells. Paclitaxel can control the process of cell division, inhibit cell growth and promote cell apoptosis by promoting the polymerization of microtubules. In addition, anti-PD-1 antibodies can affect cervical cancer cells. PD-1 antibodies and PD-L1 ligand can stimulate T cell activity, so that a large number of cells are blocked in resting phase/growth 1 phase (G0/G1) phase, inhibit cell growth and promote their apoptosis. In addition, anti-PD-1 antibody combined with paclitaxel can inhibit extracellular regulated kinase (ERK) and PI3K-Akt signaling pathway and further inhibit the expression of proteins and genes related to the mitotic process, thereby affecting cell cycle, further inhibiting the proliferation of cervical cancer cells and promoting cell apoptosis[8-17]. In the study of Li et al.[18], the effect of paclitaxel chemotherapy on nude mice with cervical cancer transplantation tumors was assessed. After paclitaxel treatment, the volume of transplanted tumors in nude mice decreased significantly. Anti-PD-1 antibody combined with paclitaxel has a better effect on inhibiting tumor tissue size than paclitaxel alone.

In the process of cell mitosis, there are multiple signaling pathways involved. This study mainly explored whether the PI3K-Akt signaling pathway mediates anti-PD-1 antibody combined with paclitaxel to exert anti-tumor effects on cervical cancer. The results show that in the observation group, the expressions of PI3K, Akt, p53 and p21 proteins were the lowest and the blank group was the highest. In addition, compared with the control group B, the difference was not significant, suggesting that anti-PD-1 antibody combined with paclitaxel may inhibit PI3K-Akt pathway activity, thereby inhibiting PI3K, Akt, p53, p21 protein expression, play an anti-tumor effect. Analyze the reason. Paclitaxel mainly promotes the polymerization of microtubules, participates in the process of cell division, phosphorylates PI3K and Akt and transmits inhibitory signals. At the same time, anti-PD-1 antibody binds to PD-L1 to inhibit PI3K-Akt signal. The expression of PI3K, Akt, p53 and p21 proteins in the pathway produces immune resistance, thereby inhibiting T cell apoptosis, further preventing cervical cancer cells from immune escape and inhibiting the progression of cervical cancer[19-21].

In summary, anti-PD-1 antibody combined with paclitaxel may inhibit the activity of PI3K-Akt pathway, thereby inhibiting the expression of PI3K, Akt, p53 and p21 proteins, controlling the division process of cervical cancer cells, promoting apoptosis and finally exerting anti-tumor effect. This study has certain limitations. For example, this study mainly explores

![Fig. 3: (A) Western blot and (B) RT-PCR respectively detect the expression of PI3K-Akt signaling pathway related proteins and mRNA](image_url)
that anti-PD-1 antibody combined with paclitaxel can mediate the PI3K-Akt pathway and participate in the division and apoptosis of cervical cancer cells, but whether the PI3K-Akt pathway is involved in the cervical cancer cell proliferation and apoptosis need to be further explored. In addition, this study only explored the possible involvement of p53, p21, PI3K and other proteins in the PI3K-Akt pathway in anti-tumor effects. Whether there are other pathway factors involved in the above process remains to be studied; Anti-PD-1 antibody combined with paclitaxel can inhibit the expression of proteins and genes related to cell mitosis, but the specific proteins and genes need to be further studied.

Conflict of interests:
The authors declared no conflict of interest.

REFERENCES